WAVE Life Sciences Ltd (WVE) FinancialsWVEWAVE Life Sciences Ltd

Evaluating the bottom line, Wave Life Sciences, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3248.33%, while the net margin is -3052.60%. These profitability ratios, combined with a Return on Equity (ROE) of -68.31%, provide a clear picture of how effectively WVE converts its operational activities into shareholder value.

In the context of the broader market, WVE competes directly with industry leaders such as ATTO and SLDB. With a market capitalization of $627.19M, it holds a significant position in the sector. When comparing efficiency, WVE's gross margin of 100.00% stands against ATTO's 100.00% and SLDB's N/A. Such benchmarking helps identify whether Wave Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% in recent quarters, but net income has been negative for multiple periods, with a net loss of $69.4 million in Q2 2026, reflecting serious financial challenges.